Skip to content

Berberis Vulgaris Consumption and Blood Pressure

Effect of Berberis Vulgaris Consumption on Blood Pressure and Plasma Lipids in Subjects With Cardiovascular Risk Factors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04084847
Enrollment
78
Registered
2019-09-10
Start date
2019-09-18
Completion date
2020-10-21
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Cardiovascular Risk Factor, Lipid Profile

Keywords

Barberry, Berberis vulgaris, Blood pressure, Lipids, Inflammation

Brief summary

The aim of this study is to investigate the effect of barberry consumption on systolic and diastolic blood pressure, serum lipids, and inflammatory status. The study will involve cases having elevated BP (129/ \< 85) and known hypertensive patients on medical treatment. Seventy people will be randomized into two groups, including intervention (barberry) or placebo groups. Before and after of 8 week intervention, 24-hour ambulatory blood pressure monitoring will be done and fasting venous blood sample will be taken to measure plasma lipids. In addition, 24-hour urine will be collected to measure its sodium content and estimate sodium intake.

Interventions

DIETARY_SUPPLEMENTberberis vulgaris=barberry

10 grams of barberry powder will be consumed daily for 8 weeks.

DIETARY_SUPPLEMENTPlacebo

Placebo powder

Sponsors

Shahid Beheshti University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* willingness to participate in the study * age between 20-65 years * having elevated BP (129/ \< 85) and known hypertensive patients on medical treatment * at least one other classical cardiovascular disease risk factors, including hyperlipidemia or diabetes mellitus

Exclusion criteria

* Unwillingness to continue participation * BMI\> 30 * patients on nitrates * high doses of statins consumption (Atorvastatin\>40 mg/day or Rosuvastatin\>20 mg/day) * consumption of vitamins or minerals supplements during past month * Chronic kidney disease stage 4 or 5

Design outcomes

Primary

MeasureTime frameDescription
blood pressureat 8 weeksmean of systolic and diastolic blood pressure of participants measured by ambulatory 24 hour blood pressure monitoring

Secondary

MeasureTime frameDescription
lipid profileat 8 weeksplasma TC, LDL-C, HDL-C, TG
plasma NOxat 8 weeksconcentration of nitrite and nitrate in plasma
Inflammatory cytokineat 8 weeksPlasma Interleukin-6

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026